India, Sept. 14 -- Whitehawk Therapeutics, Inc. (WHWK) presented new real-world analyses showing that PTK7 expression remains durable and treatment-agnostic in patients with EGFR wild-type non-small cell lung cancer, reinforcing its relevance as a next-generation antibody-drug conjugate (ADC) target.
EGFR wild-type NSCLC represents a large patient population with limited targeted options, and many individuals progress through multiple lines of standard-of-care therapy, including chemotherapy and immunotherapy. Identifying tumor targets that remain stable after treatment is critical for ADC development.
The analyses, presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, evaluated PTK7 expression in tumor samples from...